Predicting BCG Response

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT04564781
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Study Details

To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.

Key Dates

Start date
Sep 18, 2020
Status verified
Feb 2026
Primary completion
Feb 28, 2030
Completion
Feb 28, 2030

Study Design

Enrollment
400 participants (estimated)

Primary Outcome Measure

Sensitivity and specificity of multiplex immunoassay will be confirmed by surveillance cystoscopy. [ Time Frame: present through 04/30/2027 ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Medical CenterLos AngelesCalifornia90048
Amy Oppenheim
[email protected]
310-423-3713
Hideki Furuya, PhD (PRINCIPAL_INVESTIGATOR)
UCLALos AngelesCalifornia90095
Arnold Chin, MD
UCSFSan FranciscoCalifornia94143
Sima Porten, MD
University of Texas SouthwesternDallasTexas75390
Perla Lopez
[email protected]
214-648-9195

Find similar trials in Los Angeles, CA

By condition
Bladder cancer
By specialty
OncologyUrology
By research site
Cedars-Sinai Medical Center· Los Angeles, CAUCLA· Los Angeles, CAUCSF· San Francisco, CAUniversity of Texas Southwestern· Dallas, TX

Related Studies